Evidence map›Paper›PMID 31592289›Full record

ArticlePharmacy practice

Evaluation of vitamin B12 monitoring in patients on metformin in urban ambulatory care settings.

Stacy L Longo, Jessica M Ryan, Kelsey B Sheehan, Debra J Reid, Michael P Conley, Carla J Bouwmeester

Open access · diamondAbstract read
In one paragraph

Article in Pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Vitamin BBMJ open · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Stacy L LongoClinical Pharmacist. The Dimock Center, Roxbury, MA (United States). stacy.lin.longo@gmail.com.ORCID 0000-0002-2752-3405
Jessica M RyanClinical Pharmacist. Harbor Health Services Community Health Centers, Boston, MA (United States). jessica.ryan.pharmd@gmail.com.ORCID 0000-0002-8477-2176
Kelsey B SheehanClinical Pharmacist. Harbor Health Services Elder Service Plan, Mattapan, MA (United States). kelsey.sheehan3@va.gov.ORCID 0000-0001-8785-8920
Debra J ReidAssociate Clinical Professor. School of Pharmacy, Bouvé College of Health Sciences, Northeastern University. Boston, MA (United States). d.reid@northeastern.edu.ORCID 0000-0001-8966-3502
Michael P ConleySchool of Pharmacy, Bouvé College of Health Sciences, Northeastern University. Boston, MA (United States). m.conley@northeastern.edu.ORCID 0000-0003-3730-0843
Carla J BouwmeesterSchool of Pharmacy, Bouvé College of Health Sciences, Northeastern University. Boston, MA (United States). c.bouwmeester@northeastern.edu.ORCID 0000-0002-3633-354X
American Pharmacists Association · USNortheastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies linked metformin use to vitamin B12 deficiency and demonstrated that the prevalence of vitamin B12 monitoring remains low.

objectiveThis study aimed to assess the occurrence of monitoring vitamin B12 levels in a diverse population.

methodsThis was a retrospective chart review of adult patients with type 2 diabetes on metformin doses ≥ 1000 mg for ≥ 6 months at five Federally Qualified Health Centers (FQHC) and one Program of All-Inclusive Care for the Elderly (PACE). Charts were reviewed for occurrence of monitoring vitamin B12 levels in the past 5 years. Data collected included patient demographics, laboratory data, other potential vitamin B12 level lowering agents, active prescription for vitamin B12 supplementation, concomitant diabetes medications and metformin total daily dose.

resultsOf the 322 patients included, 25% had a vitamin B12 level measured in the previous five years. Among the patients with a vitamin B12 level, 87.7% were within the normal range (>350 pg/mL), 11.1% were low (200-300 pg/mL), and only one patient (1.2%) was deficient (<200 pg/mL). These patients were older (69.2 vs. 56.4, p<0.001); more likely to be white (56.8% vs. 37.8%, p=0.04); and more likely to use proton pump inhibitors (34.6% vs. 20.7%, p=0.02) and vitamin B12 supplementation (27.2% vs. 4.6%, p<0.001). Vitamin B12 monitoring differed between the FQHC (15.2%) and PACE (97.4%) sites (p<0.001). Each greater year of age was associated with a 5% increased odds of vitamin B12 monitoring (a OR: 1.05; 95% CI: 1.02-1.08).

conclusionsThe majority of patients seen at the FQHC sites did not have vitamin B12 levels monitored, however, most of the patients who were monitored had normal vitamin B12 levels, which may warrant extending the monitoring time. This finding may also support monitoring patients who have additional risk factors for vitamin B12 deficiency such as concurrent medication use with other vitamin B12 lowering agents or clinical symptoms of deficiency such as peripheral neuropathy. Future studies are needed to determine appropriate frequency of monitoring.

Indexed as

AttitudesDiabetes MellitusHealth KnowledgeMetforminPracticePrevalenceQuality of Health CareRetrospective StudiesType 2United StatesVitamin B 12Vitamin B 12 Deficiency

Identifiers

PMID31592289
PMCPMC6763298
OpenAlexW2972530296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.